VIVUS (NASDAQ:VVUS) Analyst Rating Consensus

VIVUS (NASDAQ:VVUS) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.8 by 5 Brokerage Firm. 1 Wall Street Firms have rated the stock as a strong buys. 3 Brokerage Firms have advised hold. A sell rating was given by 1 analyst.

VIVUS (NASDAQ:VVUS) stock has received a short term price target of $ 1.9 from 2 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $1.27. The higher estimate of target price is $3 , while the lower price target estimate is $1

VIVUS (NASDAQ:VVUS) witnessed a decline in the market cap on Tuesday as its shares dropped 4.31% or 0.05 points. After the session commenced at $1.15, the stock reached the higher end at $1.17 while it hit a low of $1.08. With the volume soaring to 969,670 shares, the last trade was called at $1.11. The company has a 52-week high of $2.61. The company has a market cap of $116 million and there are 104,089,388 shares in outstanding. The 52-week low of the share price is $0.915.

VIVUS Inc. has lost 5.93% in the last five trading days and dropped 4.31% in the last 4 weeks. VIVUS Inc. has dropped 1.77% during the last 3-month period . Year-to-Date the stock performance stands at 8.82%.

VIVUS, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products. It provides two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company is also developing and has completed the Phase II studies of Qsymia for the indication of OSA and diabetes. Qsymia is available in over 42,000 certified retail pharmacies across the country. STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. As of September 18, 2014, the FDA approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *